RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Recommendation |
|
Starting dose
|
0.5 mg (1 mL of 500 mcg/mL solution) diluted with 2–3 mL normal saline |
|
Titration
|
Increase to 1 mg per dose if inadequate response after 20–30 minutes |
|
Usual maintenance dose
|
0.5–1 mg every 4–6 hours |
|
Maximum dose
|
2 mg per single dose; 8 mg/day |
| Parameter | Recommendation |
|
Starting dose
|
100 mcg (1 puff) |
|
Titration
|
May increase to 200 mcg (2 puffs) if needed |
|
Usual maintenance dose
|
100–200 mcg per dose as required |
|
Maximum dose
|
400 mcg per dose; 800 mcg/day (8 puffs/day) |
| Parameter | Recommendation |
|
Starting dose
|
100 mcg (1 puff) MDI with spacer |
|
Titration
|
Not applicable — use as needed |
|
Usual maintenance dose
|
100–200 mcg per episode |
|
Maximum dose
|
400 mcg per dose; 800 mcg/day |
| Parameter | Recommendation |
|
Starting dose
|
100–200 mcg (1–2 puffs) MDI |
|
Timing
|
15–30 minutes before anticipated exertion |
|
Titration
|
Not applicable |
|
Maximum dose
|
200 mcg per occasion |
| Indication | Dosing | Duration | Notes |
|
Tocolysis (acute preterm labour) — OFF-LABEL
|
IV: 100 mcg over 10 minutes initially, then continuous infusion 1–3 mcg/min, titrated to uterine response | Short-term emergency use only (24–48 hours maximum) | Specialist only — obstetric units. Historical use; largely superseded by nifedipine and atosiban. Associated with significant maternal cardiovascular effects. Evidence basis: Historical case series; not current standard of care |
| Age Group | Starting Dose | Titration | Usual Maintenance | Maximum Dose |
|
<6 years
|
0.05–0.1 mg/kg diluted in 2–3 mL saline | Repeat after 20–30 min if needed | 0.05–0.1 mg/kg every 4–6 hours | 0.5 mg/dose |
|
6–12 years
|
0.5 mg (1 mL) diluted in 2–3 mL saline | Increase to 1 mg if inadequate response | 0.5–1 mg every 4–6 hours | 1 mg/dose |
|
>12 years (Adolescents)
|
0.5 mg diluted in 2–3 mL saline | As per adult protocol | 0.5–1 mg every 4–6 hours | 2 mg/dose |
| Age Group | Dose | Frequency | Maximum |
|
Children 4–12 years
|
100 mcg (1 puff) via spacer | As needed for symptoms | 400–600 mcg/day (4–6 puffs) |
|
Adolescents >12 years
|
100–200 mcg (1–2 puffs) | As needed | 800 mcg/day |
| Renal Function | Recommendation |
| Mild–Severe impairment | No dosage adjustment required |
| Haemodialysis | No adjustment; minimal systemic absorption via inhalation route |
| Child-Pugh Class | Score | Recommendation |
|
Class A (Mild)
|
5–6 points | No dose adjustment required |
|
Class B (Moderate)
|
7–9 points | No dose adjustment required |
|
Class C (Severe)
|
10–15 points | Use with caution; monitor for increased systemic effects if high-dose nebulisation required |
| Aspect | Details |
|
Overall safety
|
Limited human data; inhaled use likely low-risk due to minimal systemic absorption |
|
When to use
|
When short-acting beta-agonist is clearly indicated for acute bronchospasm; benefit outweighs potential risk |
|
Preferred alternatives
|
Salbutamol (more extensive safety data in pregnancy) |
|
Tocolysis use
|
Discouraged — nifedipine or atosiban preferred; if used, only under specialist inpatient supervision |
|
Monitoring required
|
Maternal: heart rate, blood pressure, blood glucose. Fetal: continuous fetal heart rate monitoring if used for tocolysis |
| Aspect | Details |
|
Compatibility
|
Likely compatible with breastfeeding when used by inhalation |
|
Expected levels in milk
|
Low — minimal systemic absorption from inhaled route |
|
Preferred alternatives
|
Salbutamol (wider safety data in lactation) |
|
Infant monitoring
|
Usually not required with standard inhaled doses; observe for irritability or tachycardia if maternal high-dose use |
| Aspect | Recommendation |
|
Starting dose
|
Same as adults — 100 mcg MDI or 0.5 mg nebulised |
|
Titration
|
Slower titration; allow longer intervals between doses |
|
Extra risks
|
Increased sensitivity to cardiovascular effects (tachycardia, palpitations, arrhythmias); tremor more pronounced; underlying cardiac disease may be unmasked |
|
Monitoring
|
Heart rate and rhythm; blood pressure; watch for angina symptoms |
|
Practical tips
|
Prefer MDI with spacer to ensure adequate drug deposition; assess inhaler technique regularly |
| Interacting Drug | Effect/Risk | Management |
|
Non-selective beta-blockers (propranolol, carvedilol, labetalol)
|
Antagonise bronchodilator effect; may precipitate bronchospasm | Avoid combination; if beta-blocker essential, use cardioselective agent (bisoprolol, metoprolol) |
|
MAO inhibitors (phenelzine, tranylcypromine, linezolid)
|
Potentiate sympathomimetic effects; risk of hypertensive crisis | Avoid combination or use with extreme caution; monitor BP closely |
|
Tricyclic antidepressants (amitriptyline, imipramine)
|
Potentiate cardiovascular effects | Use with caution; monitor heart rate and rhythm |
|
QT-prolonging drugs (azithromycin, haloperidol, ondansetron, amiodarone)
|
Additive risk of QT prolongation and arrhythmias, especially with hypokalaemia | Monitor ECG if combination unavoidable; correct electrolytes |
| Interacting Drug | Effect/Risk | Management |
|
Loop diuretics (furosemide)
|
Additive hypokalaemia risk | Monitor serum potassium; supplement as needed |
|
Thiazide diuretics
|
Additive hypokalaemia risk | Monitor potassium levels |
|
Theophylline/aminophylline
|
Potentiated bronchodilation but also increased tachycardia, tremor, and hypokalaemia risk | Monitor heart rate and potassium; may need to reduce doses |
|
Systemic corticosteroids
|
Additive hypokalaemia and hyperglycaemia | Monitor electrolytes and blood glucose with prolonged co-administration |
|
Digoxin
|
Hypokalaemia from beta-agonist may increase digoxin toxicity risk | Monitor potassium and digoxin levels |
|
Other sympathomimetics (salbutamol, adrenaline)
|
Additive cardiovascular effects | Avoid concurrent use if possible; if essential, monitor closely |
| Adverse Effect | Notes |
| Paradoxical bronchospasm | Requires immediate discontinuation; provide alternative bronchodilator |
| Cardiac arrhythmias (SVT, atrial fibrillation) | More common with high doses or in patients with underlying cardiac disease |
| Severe hypokalaemia | Especially with high-dose nebulisation combined with steroids/xanthines; may precipitate arrhythmias |
| Lactic acidosis | Rare; associated with high-dose or continuous nebulisation in severe asthma |
| Myocardial ischaemia | In patients with underlying coronary artery disease |
| Hypersensitivity reactions | Rare; discontinue immediately |
| Timing | Parameters |
|
Baseline
|
Heart rate, blood pressure, serum potassium (especially in combination therapy), blood glucose in diabetics |
|
During acute use
|
Heart rate, SpO2, symptom relief, respiratory rate; watch for paradoxical bronchospasm |
|
Repeated/continuous nebulisation
|
ECG if cardiac risk factors present; serum potassium every 6–12 hours |
|
Long-term asthma management
|
Frequency of rescue inhaler use (marker of control); ensure adequate ICS adherence; reassess if SABA use >2 times/week |
| Formulation | Price Range | Notes |
| MDI 100 mcg/actuation (200 doses) | ₹120–₹180 per inhaler | Brand-dependent |
| Nebuliser solution 500 mcg/mL (2 mL ampoule) | ₹15–₹25 per ampoule | Mono-ingredient |
| Combination nebuliser solution (Fenoterol + Ipratropium) | ₹25–₹40 per ampoule | More commonly available |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.